Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Cited by (1,000)

Items 701–800 of 1,000

1. The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer
   Xun Hui Yeo, Vignesh Sundararajan, Zhengwei Wu, Zi Jin Cheryl Phua, Yin Ying Ho, Kai Lay Esther Peh, Yi-Chia Chiu, Tuan Zea Tan, Dennis Kappei, Ying Swan Ho et al. · 2023 · Communications Biology
2. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer
   Ryota Nakamura, Tadaaki Yamada, Shinsaku Tokuda, Kenji Morimoto, Yuki Katayama, Yohei Matsui, Soichi Hirai, Masaki Ishida, Hayato Kawachi, Ryo Sawada et al. · 2024 · Cancer Letters
3. Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment
   Hye-Ryoun Kim, Jae Chol Lee, Young‐Chul Kim, Kyu Sik Kim, In‐Jae Oh, Sung Yong Lee, Tae Won Jang, Min Ki Lee, Kyeong Cheol Shin, Gwan Ho Lee et al. · 2013 · Lung Cancer
4. Axl and Mer Receptor Tyrosine Kinases: Distinct and Nonoverlapping Roles in Inflammation and Cancer?
   Ian Dransfield, Sarah L. Farnworth · 2016 · Advances in experimental medicine and biology
5. Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer
   Francesco Facchinetti, Claudia Proto, Roberta Minari, Marina Chiara Garassino, Marcello Tiseo · 2017 · Handbook of experimental pharmacology
6. Epithelial-to-Pericyte Transition in Cancer
   Jianrong Lu, Anitha Kota Shenoy · 2017 · Cancers
7. Design, synthesis and evaluation of sulfonylurea-containing 4-phenoxyquinolines as highly selective c-Met kinase inhibitors
   Xiang Nan, Yi-Fan Jiang, Hui‐Jing Li, Junhu Wang, Yan‐Chao Wu · 2019 · Bioorganic & Medicinal Chemistry
8. Novel Approaches to Target Mutant FLT3 Leukaemia
   Jörg P. Müller, Dirk Schmidt‐Arras · 2020 · Cancers
9. lncRNA GSEC Promotes the Progression of Triple Negative Breast Cancer (TNBC) by Targeting the miR-202-5p/AXL Axis
   Jianhua Zhang, Chuang Du, Linfeng Zhang, Yan Wang, Yingying Zhang, Jingruo Li · 2021 · OncoTargets and Therapy
10. Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer
    Donatella Romaniello, Alessandra Morselli, Ilaria Marrocco · 2025 · International Journal of Molecular Sciences
11. Amphiregulin mediates the hormonal regulation on Rspondin-1 expression in the mammary gland
    Cheguo Cai, Ajun Geng, Mengran Wang, Li Chun Yang, Qing Cissy Yu, Yi Arial Zeng · 2019 · Developmental Biology
12. AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model
    Tony J. Chen, Piotr Mateusz Mydel, Małgorzata Benedyk‐Machaczka, Marta Kamińska, Urszula Kałucka, Magnus Blø, Jessica Furriol, Gro Gausdal, James B. Lorens, Tarig Osman et al. · 2021 · Physiological Reports
13. Two-Front War on Cancer—Targeting TAM Receptors in Solid Tumour Therapy
    Agata Mikołajczyk, Filip Mituła, Delfina Popiel, Bozena Kaminska, Maciej Wieczorek, Jerzy Pieczykolan · 2022 · Cancers
14. The expression and significance of efferocytosis and immune checkpoint related molecules in pancancer samples and the correlation of their expression with anticancer drug sensitivity
    Lin Cheng, Bangbi Weng, Changsheng Jia, Lin Zhang, Bin Hu, Li Deng, Nan Mou, Fengjun Sun, Jing Ying Hu · 2022 · Frontiers in Pharmacology
15. AXL kinase inhibitors- A prospective model for medicinal chemistry strategies in anticancer drug discovery
    Chinmay Malvankar, Dileep Kumar · 2022 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
16. Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study
    Diego F. Chamorro, Andrés Felipe Cardona, July Katherine Rodríguez, Alejandro Ruíz-Patiño, Oscar G. Arrieta, Darwin Andrés Moreno Pérez, Leonardo Rojas, Zyanya Lucía Zatarain-Barrón, Dora V. Ardila, Lucía Viola et al. · 2023 · Targeted Oncology
17. Characteristics and molecular mechanism of drug-tolerant cells in cancer: a review
    Xian-Wen Liang, Bing Liu, Jia-Cheng Chen, Zhi Wei Cao, Feng-Ran Chu, Lin Xiong, Sheng-Zhong Wang, Jincai Wu · 2023 · Frontiers in Oncology
18. Recent discovery and development of AXL inhibitors as antitumor agents
    Z. Liu, Li Chen, Jifa Zhang, Jun Yong Yang, Xue Xiao, Lianhai Shan, Wuyu Mao · 2024 · European Journal of Medicinal Chemistry
19. SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells
    Casey G. Langdon, Norbert Wiedemann, Matthew A. Held, Ramanaiah Mamillapalli, Pinar Iyidogan, Nicholas Theodosakis, James T. Platt, Frédéric Lévy, Grégoire Vuagniaux, Shaomeng Wang et al. · 2015 · Oncotarget
20. Wrangling Phosphoproteomic Data to Elucidate Cancer Signaling Pathways
    Mark L. Grimes, Wan-Jui Lee, Laurens van der Maaten, Paul T. Shannon · 2013 · PLoS ONE
21. Associations of mRNA:microRNA for the Shared Downstream Molecules of EGFR and Alternative Tyrosine Kinase Receptors in Non-small Cell Lung Cancer
    Fengfeng Wang, Fei Meng, Lili Wang, Sze Chuen Cesar Wong, William Chi Shing Cho, Lawrence Chan · 2016 · Frontiers in Genetics
22. Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors
    Justin A. Chen, Jonathan Wesley Riess · 2020 · Journal of Thoracic Disease
23. Acquired Resistance in Lung Cancer
    Asmin Tulpule, Trever Grant Bivona · 2019 · Annual Review of Cancer Biology
24. MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma
    Ankit Jain, Krishna Patel, Sneha Maria Pinto, Aneesha Radhakrishnan, Vishalakshi Nanjappa, Manish Kumar, Remya Raja, Arun H. Patil, Anjali Kumari, Malini Manoharan et al. · 2019 · Scientific Reports
25. Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome
    Mariëtte Labots, Thang V. Pham, Richard J. Honeywell, Jaco C. Knol, Robin Beekhof, Richard de Goeij-de Haas, Henk Dekker, Maarten Neerincx, Sander R. Piersma, Johannes Cornelis van der Mijn et al. · 2020 · Cancers
26. Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid
    Gabriele Greve, Insa Schiffmann, Michael Lübbert · 2015 · Journal of Cancer Research and Clinical Oncology
27. CAR-T Cells for the Treatment of Lung Cancer
    Luisa Chocarro, Hugo Arasanz, Leticia Fernández, Ester Blanco, Miriam Echaide, Ana Bocanegra, Lucía Teijeira, Maider Garnica, Idoia Morilla, Maite Martínez-Aguillo et al. · 2022 · Life
28. Antibody-drug conjugates: beyond current approvals and potential future strategies
    Siddharth Menon, Sagun Parakh, Andrew Mark Scott, Hui Kong Gan · 2022 · Exploration of Targeted Anti-tumor Therapy
29. Axl is a novel target of withaferin A in the induction of apoptosis and the suppression of invasion
    Seon Min Woo, Kyoung‐jin Min, Shin Kim, Jong‐Wook Park, Dong‐Eun Kim, Sang‐Hyun Kim, Yung Hyun Choi, Taeg Kyu Kwon · 2014 · Biochemical and Biophysical Research Communications
30. AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells
    Morimoto, Kenji, Yamada, Tadaaki, Hirai, Soichi, Katayama, Yuki, Fukui, Sarina, Sawada, Ryo, Tachibana, Yusuke, Matsui, Yohei, Nakamura, Ryota, Ishida, Masaki et al. · 2024 · Cancer Letters
31. Vitamin D3 Metabolites Demonstrate Prognostic Value in EGFR-Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance
    Tatiana Shaurova, Grace Kho Dy, Sebastiano Battaglia, Alan David Hutson, Letian Zhang, Yunkai Zhang, Christine Marie Lovly, Mukund Seshadri, David W. Goodrich, Candace S. Johnson et al. · 2020 · Cancers
32. 6-Shogaol Overcomes Gefitinib Resistance via ER Stress in Ovarian Cancer Cells
    Tae Woo Kim, Hee Gu Lee · 2023 · International Journal of Molecular Sciences
33. Genomic aberrations guiding treatment of non-small cell lung cancer patients
    Ali Saber, Anthonie J. van der Wekken, T. Jeroen N. Hiltermann, Klaas Kok, Anke van den Berg, Harry J.M. Groen · 2015 · Cancer Treatment Communications
34. Compound 15c, a Novel Dual Inhibitor of EGFRL858R/T790M and FGFR1, Efficiently Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance of Non-Small-Cell Lung Cancers
    Gaozhi Chen, Yuyan Bao, Qiaoyou Weng, Yingxin Zhao, Xiaoyao Lu, Lili Fu, Lingfeng Chen, Zhiguo Liu, Xiaomin Zhang, Guang Liang · 2020 · Frontiers in Pharmacology
35. AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation
    Yu‐Mi Yang, Yoon Jin Jang, Sang‐Hyuk Lee, Beodeul Kang, Sun Min Lim · 2020 · Lung Cancer
36. Clinical Impact of the Epithelial-Mesenchymal Transition in Lung Cancer as a Biomarker Assisting in Therapeutic Decisions
    Julien Ancel, Maxime Dewolf, Gaëtan Deslée, Béatrice Nawrocki‐Raby, Véronique Dalstein, Christine Gilles, Myriam Polette · 2020 · Cells Tissues Organs
37. Epithelial-Mesenchymal Transition Induces GSDME Transcriptional Activation for Inflammatory Pyroptosis
    Chenqiang Jia, Zhuqing Zhang, Jun Tang, Mei‐Chun Cai, Jingyu Zang, Kaixuan Shi, Yunheng Sun, Jie Wu, Hailei Shi, Weiping Shi et al. · 2021 · Frontiers in Cell and Developmental Biology
38. Patient-derived xenograft models for oncology drug discovery
    Gang Li · 2015 · Journal of Cancer Metastasis and Treatment
39. Uses of dimedone for the synthesis of new heterocyclic derivatives with anti-tumor, c-Met, tyrosine, and Pim-1 kinases inhibitions
    Rafat M. Mohareb, Fatma Omar Al Farouk, Wagnat W. Wardakhan · 2018 · Medicinal Chemistry Research
40. Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer
    Ziyang Jiang, Zhihan Gu, Xiao-Min Yu, Tao Cheng, Bofu Liu · 2024 · Frontiers in Oncology
41. Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway
    Qi Sun, Zhihua Lü, Yanpeng Zhang, Dong Xue, Huayu Xia, Junjun She, Fanni Li · 2022 · Cells
42. Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions
    Jia Zhong, Hua Bai, Zhijie Wang, Jianchun Duan, Wei Zhuang, Di Wang, Rui Wan, Jiachen Xu, Kailun Fei, Zixiao Ma et al. · 2023 · Frontiers of Medicine
43. A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib
    Arturo Simoni Nieves, Moshit Lindzen, Suvendu Giri, Nitin Gupta, Rishita Chatterjee, Boobash-Raj Selvadurai, Marieke Van Daele, Danielle Love, Yuya Haga, Donatella Romaniello et al. · 2024 · Cell Reports Medicine
44. Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
    Marzia Del Re, Enrico Vasile, Alfredo Falcone, Romano Danesi, Iacopo Petrini · 2014 · Expert Review of Molecular Diagnostics
45. The role of next-generation sequencing in the differential diagnosis of composite neoplasms
    Andres Martin Acosta, Mohamed Rizwan Haroon Al Rasheed, Michael R. Pins, Kristina R. Borgen, Dipti Panchal, Magdalena Rogozinska, Elizabeth Louise Wiley, Frederick G. Behm, Gayatry Mohapatra · 2018 · Human Pathology
46. Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation
    Ou Yamaguchi, Kyoichi Kaira, Atsuto Mouri, Ayako Shiono, Kosuke Hashimoto, Yu Miura, Fuyumi Nishihara, Yoshitake Murayama, Kunihiko Kobayashi, Hiroshi Kagamu · 2019 · Cancer Chemotherapy and Pharmacology
47. Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system
    Mio Ikeda, Yasuhiro Koh, Shunsuke Teraoka, Koichi Sato, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Hiroaki Akamatsu, Yuichi Ozawa, Keiichiro Akamatsu et al. · 2020 · Cancer Medicine
48. Reduced PHLPP Expression Leads to EGFR-TKI Resistance in Lung Cancer by Activating PI3K-AKT and MAPK-ERK Dual Signaling
    Wei Wang, Xinhang Xia, Kuifei Chen, Chen Meng, Yinnan Meng, Dongqing Lv, Haihua Yang · 2021 · Frontiers in Oncology
49. Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments
    Joshua E. Reuss, Laura Gosa, Stephen V. Liu · 2021 · Clinical Lung Cancer
50. Combating Acquired Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
    Christine Marie Lovly · 2015 · American Society of Clinical Oncology Educational Book
51. Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models
    Sun Min Lim, San-Duk Yang, Sangbin Lim, Seong Gu Heo, Daniel Stetson, Aleksandra A. Markovets, Rafati Minoo, Kyoung‐Ho Pyo, Mi Ran Yun, Min Hee Hong et al. · 2022 · Therapeutic Advances in Medical Oncology
52. AXL Mediates TRAIL Resistance in Esophageal Adenocarcinoma
    Jun Hong, Abbes Belkhiri · 2013 · Neoplasia
53. Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression
    Katsuaki Sato, Kenichi Suda, Shigeki Shimizu, Kazuko Sakai, Hiroshi Mizuuchi, Kenji Tomizawa, Toshiki Takemoto, Kazuto Nishio, Tetsuya Mitsudomi · 2016 · PLoS ONE
54. Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression
    Tanaka, Hiroaki, Sakagami, Hideki, Kaneko, Naoki, Konagai, Satoshi, Yamamoto, Hiroko, Matsuya, Takahiro, Yuri, Masatoshi, Yamanaka, Yosuke, Mori, Masamichi, Takeuchi, Masahiro et al. · 2019 · Molecular Cancer Therapeutics
55. ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR -Mutant Advanced Non–Small Cell Lung Cancer Treated with First-Line Osimertinib
    Zofia Piotrowska, Myung‐Ju Ahn, Pei Jye Voon, Yong Kek Pang, Soon Hin How, S. Kim, Diego Luigi Cortinovis, Javier de Castro, Marcello Tiseo, Delvys Rodríguez‐Abreu et al. · 2026 · Cancer Discovery
56. Ribonuclease 4 is associated with aggressiveness and progression of prostate cancer
    Nil Vanli, Jinghao Sheng, Shuping Li, Zhengping Xu, Guo‐fu Hu · 2022 · Communications Biology
57. Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: Sensitivity and resistance
    Shinji Takeuchi, Seiji Yano · 2014 · Respiratory Investigation
58. Bidirectional signaling between TM4SF5 and IGF1R promotes resistance to EGFR kinase inhibitors
    Jungeun Choi, Minkyung Kang, Seo Hee Nam, Gyu‐Ho Lee, Hye‐Jin Kim, Jihye Ryu, Jin‐Gyu Cheong, Jae Woo Jung, Tai Young Kim, Ho‐Young Lee et al. · 2015 · Lung Cancer
59. Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer
    Jin Kyung Rho, In Yong Lee, Yun Jung Choi, Chang‐Min Choi, Jae-Young Hur, Jong Sung Koh, Jaekyoo Lee, Byung‐Chul Suh, Ho‐Juhn Song, Paresh Salgaonkar et al. · 2017 · Cancer Research
60. AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis
    Yun Jung Choi, Ji Hye Kim, Jin Kyung Rho, Joong‐Sun Kim, Chang‐Min Choi, Woo Sung Kim, Jaekyoung Son, Jae Cheol Lee · 2017 · Oncology Reports
61. AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier
    Masahiro Seike, Cheol-Hong Kim, Fenfei Zou, Rintaro Noro, Mika Chiba, Arimi Ishikawa, Shinobu Kunugi, Kaoru Kubota, Akihiko Gemma · 2017 · Oncology Reports
62. Long non-coding RNAs in lung cancer: implications for lineage plasticity-mediated TKI resistance
    Tongyan Liu, Chencheng Han, Panqi Fang, Hongyu Zhu, Siwei Wang, Zhifei Ma, Quanli Zhang, Wenjia Xia, Jie Wang, Lin Xu et al. · 2020 · Cellular and Molecular Life Sciences
63. Tumor plasticity and therapeutic resistance in oncogene-addicted non-small cell lung cancer: from preclinical observations to clinical implications
    Gouji Toyokawa, Francesca Bersani, Paolo Bironzo, Francesca Picca, Fabrizio Tabbò, Naoki Haratake, Tomoyoshi Takenaka, Takashi Seto, Tomoharu Yoshizumi, Silvia Novello et al. · 2023 · Critical Reviews in Oncology/Hematology
64. Synthesis and Antitumor Activity of Novel 4‐(2‐ F luorophenoxy)quinoline Derivatives Bearing the 4‐ O xo‐1,4‐dihydroquinoline‐3‐carboxamide Moiety
    Sai Li, Rui Jiang, Mingze Qin, Haicheng Liu, Guangyan Zhang, Ping Gong · 2013 · Archiv der Pharmazie
65. A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics
    Ozhan Ocal, V. Pashkov, R. Kollipara, Yalda Zolghadri, V. H. Cruz, Michael A. Hale, Blake R. Heath, A. Artyukhin, A. Christie, P. Tsoulfas et al. · 2015 · Disease Models & Mechanisms
66. Small cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma
    Greta Alì, Rossella Bruno, Mirella Giordano, Irene Prediletto, Letizia Marconi, Simona Zupo, Franco Fedeli, Alessandro Ribechini, Antonio Chella, Gabriella Fontanini · 2016 · Oncology Letters
67. A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine
    Martin Sattler, Isa Mambetsariev, Jeremy Fricke, Tingting Tan, Sariah Liu, Nagarajan Vaidehi, Evan P. Pisick, Tamara Mirzapoiazova, Adam Rock, Amartej Merla et al. · 2023 · Journal of Clinical Medicine
68. SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer
    Ji Zhou, Xu‐Chao Zhang, Shan Xue, Mengdi Dai, Yueliang Wang, Peng Xia, Jianjiao Chen, Xinyi Wang, Yanyan Shen, Hui Qin et al. · 2023 · Signal Transduction and Targeted Therapy
69. Gas6 ameliorates intestinal mucosal immunosenescence to prevent the translocation of a gut pathobiont, Klebsiella pneumoniae, to the liver
    Hitoshi Tsugawa, Takuto Ohki, Shogo Tsubaki, Rika Tanaka, Juntaro Matsuzaki, Hidekazu Suzuki, Katsuto Hozumi · 2023 · PLoS Pathogens
70. Strategies to Overcome Acquired Resistances Conferred by Mutations in the Kinase Domain of Egfr
    Sang Min Lim, Yujeong Jeong, Sungwoo Hong · 2016 · Future Medicinal Chemistry
71. Virtual screening of natural compounds as inhibitors of EGFR 696-1022 T790M associated with non-small cell lung cancer
    Mahesha Nand, Priyanka Maiti, Ragini Pant, Madhulata Kumari, Subhash Chandra, Veena Pande · 2016 · Bioinformation
72. Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer
    Simon Vyse, Annie Howitt, Paul H. Huang · 2017 · Journal of Molecular Biology
73. Transcriptional upregulation of c‐ MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma
    Jun Hong, Selma Maacha, Abbes Belkhiri · 2018 · Molecular Oncology
74. FHITlow / pHER2high signature in non‐small cell lung cancer is predictive of anti‐HER2 molecule efficacy
    Jordan Da silva, Amina Jouida, Julien Ancel, Véronique Dalstein, Julie Routhier, Gonzague Delépine, Jérôme Cutrona, Antoine Jonquet, Maxime Dewolf, Philippe L. Birembaut et al. · 2020 · The Journal of Pathology
75. Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective
    Julia E Lai-Kwon, Crescens Tiu, Abhijit Pal, Sachin Khurana, Anna Rachel Minchom · 2021 · Critical Reviews in Oncology/Hematology
76. Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors
    Yuya Haga, Ilaria Marrocco, Ashish Noronha, Mary Luz Uribe, Nishanth Belugali Nataraj, Arunachalam Sekar, Diana Drago Garcia, Simone Borgoni, Moshit Lindzen, Suvendu Giri et al. · 2021 · Cancer Research
77. Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells
    Shaojia Wang, Chao Liu, Qing Lei, Zhengwei Wu, Xiangshuai Miao, Debing Zhu, Xu Yang, Na Li, Mingwei Tang, Yan Chen et al. · 2021 · Respiratory Research
78. Identification of Hub Genes and Small Molecule Drugs Associated with Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer
    Guangda Li, Yunfei Ma, Mingwei Yu, Xiaoxiao Li, Xinjie Chen, Yu Gao, Peiyu Cheng, Gan‐Lin Zhang, Xiaomin Wang · 2021 · Journal of Cancer
79. Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
    Youjin Chang, Seon Ye Kim, Yun Jung Choi, Kwang Sup So, Jin Kyung Rho, Woo Sung Kim, Jae Cheol Lee, Jin-Haeng Chung, Chang‐Min Choi · 2013 · Tuberculosis & respiratory diseases
80. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells
    A. MAUREEN ROUHI, Christina V. Miller, Sarah Grasedieck, Stefanie Reinhart, Britta Stolze, Hartmut Döhner, Florian C. Kuchenbauer, Lars Bullinger, Stefan Fröhling, Claudia Scholl · 2016 · Oncotarget
81. Bufalin down-regulates Axl expression to inhibit cell proliferation and induce apoptosis in non-small-cell lung cancer cells
    Nam‐Yi Kim, Young‐Ah Suh, Soyoung Kim, ChuHee Lee · 2020 · Bioscience Reports
82. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma
    Kara Marie Ruicci, Jalna Meens, Paul Plantinga, William Stecho, Nicole C. Pinto, John Yoo, Kevin Fung, S. Danielle MacNeil, Joe S. Mymryk, John W. Barrett et al. · 2020 · Journal of Experimental & Clinical Cancer Research
83. Emerging drugs for EGFR-mutated non-small cell lung cancer
    Vineeth Sukrithan, Lei Deng, Alexander Barbaro, Haiying Cheng · 2018 · Expert Opinion on Emerging Drugs
84. Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors
    Yuxiang Ma, Furong Liu, Yang Zhang, Qun Chen, Zhiqiang Chen, Qianwen Liu, Yan Huang, Yunpeng Yang, Wenfeng Fang, Ning Xi et al. · 2022 · Frontiers in Immunology
85. Collateral Chemoresistance to Anti-Microtubule Agents in a Lung Cancer Cell Line with Acquired Resistance to Erlotinib
    Hiroshi Mizuuchi, Kenichi Suda, Katsuaki Sato, Shuta Tomida, Yoshihiko Fujita, Yoshihisa Kobayashi, Yoshihiko Maehara, Yoshitaka Sekido, Kazuto Nishio, Tetsuya Mitsudomi · 2015 · PLoS ONE
86. Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine
    Martin Pool, H. Rudolf de Boer, Marjolijn N. Lub–de Hooge, Marcel A.T.M. van Vugt, Elisabeth G.E. de Vries · 2017 · Theranostics
87. Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization
    Patrick O. Bolan, Asaf Zviran, Lisa Brenan, Joshua S. Schiffman, Neville N. Dusaj, Amy B. Goodale, Federica Piccioni, Cory M. Johannessen, Dan Avi Landau · 2019 · Cell Systems
88. Gas6/MerTK signaling is negatively regulated by NF-κB and supports lung carcinogenesis
    Sergey V. Novitskiy, Rinat Zaynagetdinov, Georgii Vasiukov, Sergey S Gutor, Wei Han, Ana Paula Moreira Serezani, Anton Matafonov, Linda A. Gleaves, Taylor P. Sherrill, Vasiliy V. Polosukhin et al. · 2019 · Oncotarget
89. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling
    Minhai Dong, Qungen Xiao, Jinyang Hu, Fangling Cheng, Po Zhang, Weifeng Zong, Qiao-Ying Tang, Xiaopeng Li, Feng Mao, Yue He et al. · 2020 · Cancer Gene Therapy
90. Autocrine Signaling of NRP1 Ligand Galectin-1 Elicits Resistance to BRAF-Targeted Therapy in Melanoma Cells
    Sabrina Rizzolio, Simona Corso, Silvia Giordano, Luca Tamagnone · 2020 · Cancers
91. Transcriptome Profiling of Acquired Gefitinib Resistant Lung Cancer Cells Reveals Dramatically Changed Transcription Programs and New Treatment Targets
    Nan Wei, Yongan Song, Fan Zhang, Zhifu Sun, Xiaoju Zhang · 2020 · Frontiers in Oncology
92. An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKi-resistant cells by modulating miR-335 expression
    Debjani Pal, Polona Šafarič Tepeš, Trine Lindsted, Ingrid Ibarra, Amaia Lujambio, Vilma Jiménez Sabinina, Şerif Şentürk, Madison A. Miller, Navya Korimerla, Jiahao Huang et al. · 2021 · eLife
93. KITlow Cells Mediate Imatinib Resistance in Gastrointestinal Stromal Tumor
    Sudeep Banerjee, Hyunho Yoon, Stephanie Ting, Chih‐Min Tang, Mayra Yebra, Alexander T. Wenzel, Huwate Yeerna, Jill P. Mesirov, Robert J. Wechsler‐Reya, Pablo Tamayo et al. · 2021 · Molecular Cancer Therapeutics
94. GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis
    Shaina F. Bruce, Kevin Cho, Hollie M Noia, Elena E. Lomonosova, Elizabeth C. Stock, Alyssa Oplt, Barbara Blachut, Mary Margaret Mullen, Lindsay M. Kuroki, Andrea R. Hagemann et al. · 2022 · Molecular Cancer Therapeutics
95. Research Progress of Axl Inhibitors
    Zhigang Sun, Jianhua Liu, Jinmai Zhang, Yong Qian · 2019 · Current Topics in Medicinal Chemistry
96. Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS‐mutated ovarian cancer cells with high AXL expression
    Shiori Umemura, Yoshihiro Sowa, Yosuke Iizumi, Jo Kitawaki, Toshiyuki Sakai · 2020 · Cancer Science
97. Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation
    Keunchil Park, Gee‐Chen Chang, Giuseppe Curigliano, Wan‐Teck Lim, Ross Andrew Soo, Miguel Ángel Molina‐Vila, Valérie Cattan, Hélène Darville, Eric Gandossi, Veronika Smutná et al. · 2021 · Lung Cancer
98. Valproic acid, an inhibitor of class I histone deacetylases, reverses acquired Erlotinib-resistance of lung adenocarcinoma cells: a Connectivity Mapping analysis and an experimental study.
    Wenlei Zhuo, Liang N. Zhang, Yi Zhun Zhu, Qichao Xie, Bo Zhu, Zhengtang Chen · 2015 · Europe PMC (PubMed Central)
99. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
    Kyoung Min Cho, Bhumsuk Keam, Tae Min Kim, Se‐Hoon Lee, Dong‐Wan Kim, Dae Seog Heo · 2015 · The Korean Journal of Internal Medicine
100. Targeting the AXL signaling pathway in ovarian cancer
     Ruby Yun‐Ju Huang, Jane Antony, Tuan Zea Tan, David S.P. Tan · 2016 · Molecular & Cellular Oncology